PTCT logo

PTC Therapeutics (PTCT) Company Overview

Profile

Full Name:

PTC Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 20, 2013

Indexes:

Not included

Website:

http://www.ptcbio.com

Description:

PTC Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for the treatment of rare diseases. PTC Therapeutics, Inc. was founded in 1998, with its headquarters located in South Plainfield, New Jersey. PTC Therapeutics offers products such as Translarna and Emflaza for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; Tegsedi and Waylivra for the treatment of rare diseases in Latin American and Caribbean countries. The company is also developing a range of gene therapy candidates for the treatment of rare monogenic diseases affecting the central nervous system, including PTC-AADC for the treatment of a rare CNS disorder resulting from reduction.

Key Details

Price

$51.80

Market Cap

$4.09 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$806.78 M(-13.97% YoY)

Annual EPS

-$4.73(+43.49% YoY)

PE Ratio

-

Annual ROE

33.08%

Annual Debt To Equity

-2.16

Beta

1.30

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 28, 25 JP Morgan
Overweight
Feb 18, 25 RBC Capital
Outperform
Feb 12, 25 Citigroup
Sell
Feb 3, 25 Cantor Fitzgerald
Overweight
Jan 15, 25 Cantor Fitzgerald
Overweight
Dec 13, 24 Morgan Stanley
Overweight
Dec 4, 24 Goldman Sachs
Sell
Dec 4, 24 Citigroup
Sell
Dec 3, 24 UBS
Buy
Dec 3, 24 Barclays
Equal-Weight

Screeners with PTCT included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks with high beta
Most recommended stocks
Best performing stocks last 3 months
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector
All stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$51.80
PTCT price is $51.80

Price All-time High

$77.53
PTCT price is currently -33.19% below its historical high of $77.53

Price Analysts Target

$63.00
PTCT price is currently -17.78% lower than the consensus analysts' forecast

Price Today Change

-0.23%
PTCT price is down -0.23% today

Price YTD Change

+14.75%
PTCT price is up +14.75% since January 1st

Price 3-Year Change

+55.42%
PTCT price is up +55.42% over the past 3 years

Market cap

Market Cap

$4.09 B
PTCT market capitalization is $4.09 billion

Market Cap 3-Year Change

+71.76%
PTCT market capitalization is up +71.76% over the past 3 years

Market Cap All-time High

$4.80 B
PTCT market capitalization is currently -14.97% below its historical high of $4.80 billion

Market Cap Sector Rank

87.9%
PTCT market capitalization is higher than 87.9% of companies in Healthcare sector

Technical

Beta

1.30
PTCT beta is 1.30

200-day SMA

$39.90
PTCT price is currently +29.83% above its 200-day simple moving average

14-day RSI

57.26
PTCT 14-day relative strength index is 57.26

30-day Relative Volume

1.15
PTCT 30-day relative volume is 1.15

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$806.78 M
PTCT annual revenue is $806.78 million

Annual Revenue Analysts Estimate

$948.65 M
PTCT annual revenue is currently -14.96% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

-13.97%
PTCT annual revenue is down -13.97% year-on-year

Annual Revenue Sector Rank

79.36%
PTCT annual revenue is higher than 79.36% of companies in Healthcare sector

Profit

Annual Gross Profit

$749.38 M
PTCT annual gross profit is $749.38 million

Annual Gross Margin

92.89%
PTCT annual gross profit margin is 92.89%

Annual Operating Profit

-$146.75 M
PTCT annual operating income is -$146.75 million

Annual Operating Margin

-18.19%
PTCT annual operating profit margin is -18.19%

Annual Net Income

-$363.30 M
PTCT annual net profit is -$363.30 million

Annual Net Margin

-45.03%
PTCT annual net profit margin is -45.03%

EPS

Annual EPS

-$4.73
PTCT annual earnings per share is -$4.73

Annual EPS Analysts Estimate

-$3.62
PTCT annual earnings per share is currently +30.54% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+43.49%
PTCT annual earnings per share is up +43.49% year-on-year

Annual EPS Sector Rank

23.75%
PTCT annual earnings per share is higher than 23.75% of companies in Healthcare sector

ROA & ROE

Annual ROA

-20.18%
PTCT annual return on assets is -20.18%

Annual ROE

33.08%
PTCT annual return on equity is 33.08%

EBIT & EBITDA

Annual EBIT

-$196.13 M
PTCT annual earnings before interest & taxes is -$196.13 million

Annual EBITDA

-$120.46 M
PTCT annual EBITDA is -$120.46 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
PTCT price to earnings ratio value is unknown

PE Ratio Sector Rank

-
PTCT price to earnings ratio is unknown

PB Ratio

PB Ratio

-3.72
PTCT price to book ratio is -3.72

PB Ratio Sector Rank

5.03%
PTCT price to book ratio is higher than 5.03% of companies in Healthcare sector

PS Ratio

PS Ratio

5.06
PTCT price to sales ratio is 5.06

PS Ratio Sector Rank

63.64%
PTCT price to sales ratio is higher than 63.64% of companies in Healthcare sector

Enterprise value

Enterprise Value

$5.78 B
PTCT enterprise value is $5.78 billion

Enterprise Value Sector Rank

88.7%
PTCT enterprise value is higher than 88.7% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-47.95
PTCT EV/EBITDA is -47.95

EV/EBITDA Sector Rank

2.74%
PTCT EV/EBITDA is higher than 2.74% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

2.35
PTCT annual current ratio is 2.35

Annual Quick Ratio

2.31
PTCT annual quick ratio is 2.31

Leverage

Annual Debt To Equity

-2.16
PTCT annual debt to equity ratio is -2.16

Annual Interest Coverage Ratio

-1.17
PTCT annual interest coverage ratio is -1.17

Risk & Stability

Piotroski F-Score

3
PTCT piotroski f-score is 3

Altman Z-Score

-1.47
PTCT altman z-score is -1.47

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$1.71 B
PTCT annual total assets is $1.71 billion

Annual Non Current Assets

$339.49 M
PTCT annual long term assets is $339.49 million

Annual Current Assets

$1.37 B
PTCT annual total current assets is $1.37 billion

Annual Cash & Cash Equivalents

$779.71 M
PTCT annual cash & cash equivalents is $779.71 million

Equity

Annual Book Value

-$1.10 B
PTCT annual book value is -$1.10 billion

Annual Working Capital

$784.55 M
PTCT annual working capital is $784.55 million

Liabilities

Annual Total Liabilities

$2.80 B
PTCT annual total liabilities is $2.80 billion

Annual Total Long Term Liabilities

$2.22 B
PTCT annual total long term liabilities is $2.22 billion

Annual Current Liabilities

$580.98 M
PTCT annual total current liabilities is $580.98 million

Annual Accounts Payable

$17.27 M
PTCT annual accounts payable is $17.27 million

Debt

Annual Total Debt

$2.47 B
PTCT annual total debt is $2.47 billion

Annual Total Debt 1-Year Change

+10.85%
PTCT annual total debt is up +10.85% year-on-year

Annual Long Term Debt

$2.20 B
PTCT annual long term debt is $2.20 billion

Annual Short Term Debt

$271.18 M
PTCT annual short term debt is $271.18 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$953.53 M
PTCT annual total expenses is $953.53 million

Annual Operating Expenses

$896.13 M
PTCT annual total operating expenses is $896.13 million

Annual Cost Of Goods Sold

$57.40 M
PTCT annual cost of goods sold is $57.40 million

Annual SGA

$300.91 M
PTCT annual SGA is $300.91 million

Annual D&A

$75.66 M
PTCT annual depreciation & amortization is $75.66 million

Annual Interest Expense

$166.99 M
PTCT annual interest expense is $166.99 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$107.69 M
PTCT annual cash flow from operations is -$107.69 million

Annual CFO 1-Year Change

+32.02%
PTCT annual cash flow from operations is up +32.02% year-on-year

Annual CFI

$44.18 M
PTCT annual cash flow from investing activities is $44.18 million

Annual CFI 1-Year Change

+125%
PTCT annual cash flow from investing activities is up +125% year-on-year

Annual CFF

$255.87 M
PTCT annual cash flow from financing activities is $255.87 million

Annual CFF 1-Year Change

-60.42%
PTCT annual cash flow from financing activities is down -60.42% year-on-year

Free CashFlow

Annual FCF

-$181.94 M
PTCT annual free cash flow is -$181.94 million

Annual FCF 1-Year Change

+34.8%
PTCT annual free cash flow is up +34.8% year-on-year

CAPEX

Annual CAPEX

$74.25 M
PTCT annual capital expenditures is $74.25 million

Annual CAPEX 1-Year Change

-38.44%
PTCT annual capital expenditures is down -38.44% year-on-year

Institutional Ownership

Similar stocks

OSCR logo
Oscar Health (OSCR)
ITGR logo
Integer Holdings (ITGR)
PRGO logo
Perrigo (PRGO)
ADMA logo
ADMA Biologics (ADMA)
PBH logo
Prestige Consumer Healthcare (PBH)
RDNT logo
RadNet (RDNT)
ZLAB logo
Zai Lab Limited (ZLAB)
SWTX logo
SpringWorks Therapeutics (SWTX)
ACLX logo
Arcellx (ACLX)

FAQ

  • What is the ticker symbol for PTC Therapeutics?
  • Does PTC Therapeutics pay dividends?
  • What sector is PTC Therapeutics in?
  • What industry is PTC Therapeutics in?
  • What country is PTC Therapeutics based in?
  • When did PTC Therapeutics go public?
  • Is PTC Therapeutics in the S&P 500?
  • Is PTC Therapeutics in the NASDAQ 100?
  • Is PTC Therapeutics in the Dow Jones?
  • When was PTC Therapeutics's last earnings report?
  • When does PTC Therapeutics report earnings?
  • Should I buy PTC Therapeutics stock now?

What is the ticker symbol for PTC Therapeutics?

The ticker symbol for PTC Therapeutics is NASDAQ:PTCT

Does PTC Therapeutics pay dividends?

No, PTC Therapeutics does not pay dividends

What sector is PTC Therapeutics in?

PTC Therapeutics is in the Healthcare sector

What industry is PTC Therapeutics in?

PTC Therapeutics is in the Biotechnology industry

What country is PTC Therapeutics based in?

PTC Therapeutics is headquartered in United States

When did PTC Therapeutics go public?

PTC Therapeutics's initial public offering (IPO) was on June 20, 2013

Is PTC Therapeutics in the S&P 500?

No, PTC Therapeutics is not included in the S&P 500 index

Is PTC Therapeutics in the NASDAQ 100?

No, PTC Therapeutics is not included in the NASDAQ 100 index

Is PTC Therapeutics in the Dow Jones?

No, PTC Therapeutics is not included in the Dow Jones index

When was PTC Therapeutics's last earnings report?

PTC Therapeutics's most recent earnings report was on Feb 27, 2025

When does PTC Therapeutics report earnings?

The date for PTC Therapeutics's next earnings report has not been announced yet

Should I buy PTC Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions